Belite Bio (BLTE)

• Market cap: $2.15B
• 1 day: 2.70%
• 5 days: 6.59%
• 1 month: 5.30%
• 3 months: 6.02%
• 6 months: 17.73%
• Year to date: 0.90%
• 1 year: 33.35%
• 5 years: 517.00%
• 10 years: 517.00%
• Sector: Healthcare
• Industry: Biotechnology

About: Belite Bio Inc is a clinical-stage biopharmaceutical drug development company focused on novel therapeutics targeting untreatable eye diseases involving retinal degeneration such as atrophic age-related macular degeneration and autosomal recessive Stargardt disease or STGD1, both of which progressively to permanent blindness, and metabolic diseases such as non-alcoholic fatty liver disease, or NAFLD, nonalcoholic steatohepatitis, or NASH, type 2 diabetes, or T2D, and gout.

Employees: 25

Fund manager confidence

Based on 2025 Q2 regulatory disclosures by fund managers ($100M+ AUM)

20% more repeat investments, than reductions

Existing positions increased: 6 | Existing positions reduced: 5

0% more funds holding

Funds holding: 18 [Q1] → 18 (+0) [Q2]

0% more first-time investments, than exits

New positions opened: 6 | Existing positions closed: 6

0.22% less ownership

Funds ownership: 0.46% [Q1] → 0.25% (-0.22%) [Q2]

55% less capital invested

Capital invested by funds: $9.91M [Q1] → $4.51M (-$5.4M) [Q2]

Research analyst outlook

1 Wall Street Analyst provided 1 year price targets over the past 3 months

• Low target: $100 53% upside
• Avg. target: $100 53% upside
• High target: $100 53% upside

1 analyst rating

• positive: 1 100%
• neutral: 0 0%
• negative: 0 0%

HC Wainwright & Co. Yi Chen

53% upside $100

Buy Reiterated

3 Jul 2025